The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the agency said inhibits the generic drug market. The Federal Trade Commission ...
In an attempt to curb inaccurate patent listings in the Food and Drug Administration’s “Orange Book,” a list of drugs the FDA has deemed safe and effective, the Federal Trade Commission has ...
The warning letters don't specify how the drugmakers are flouting patent regulations, or what criteria the FTC uses to make that determination. The Federal Trade Commission on Tuesday challenged ...
AIDS Healthcare Foundation (AHF) voiced support for the U.S. Federal Trade Commission (FTC) taking action this week to challenge several major pharmaceutical companies, including GSK, for ...
On April 30, 2024, the Federal Trade Commission (FTC) announced that it sent a new set of warning letters to ten pharmaceutical companies. The letters inform the companies that the FTC has ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In Part 1 of this exclusive video interview, MedPage Today ...